Humanized 3F8 Anti-GD2Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma
Author:
Affiliation:
1. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Reference26 articles.
1. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.;Simon;BMC Cancer,2011
2. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.;Yu;N Engl J Med,2010
3. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.;Cheung;J Clin Oncol,2012
4. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.;Kushner;Oncoimmunology,2015
5. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.;Cheung;Int J Cancer,2014
Cited by 95 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Protocol for assessing GD2 on formalin-fixed paraffin-embedded tissue sections using immunofluorescence staining;STAR Protocols;2024-09
2. Omalizumab for Treatment of Anti-GD2 Antibody-Related Urticaria;Journal of Pediatric Hematology/Oncology;2024-08-22
3. Defining neuroblastoma: from origin to precision medicine;Neuro-Oncology;2024-08-05
4. Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets;2024-07-02
5. Long Prime–Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine;Vaccines;2024-05-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3